Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 17Active not recruiting 9Suspended 2Withdrawn 1Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 6CNS 6Other hematologic neoplasm 5Lymphoid 4Gynecologic 4Breast 4Thoracic 3Sarcoma 3Dermatologic 3Plasma cell 2Myeloid 2Head & Neck 2Tumor-Agnostic 1Other solid neoplasm 1Other 1

Conditions

Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 5Cisplatin 5Gemcitabine 4trametinib 2repotrectinib 2pembrolizumab 2enzalutamide 2atezolizumab 2Surveys and Questionnaires 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Nivolumab 2Interviews as Topic 2Docetaxel 2Cetuximab 2Carboplatin 2vinflunine 1veliparib 1vadimezan 1toripalimab 1talazoparib 1sintilimab 1reolysin 1pixantrone 1pertuzumab 1peginterferon alfa-2a 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Specimen Handling × Tumor-Agnostic × Clear all
NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Mayo Clinic

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡